Spero MD - InMode Chief Officer
| INMD Stock | USD 18.56 0.28 1.49% |
Insider
Spero MD is Chief Officer of InMode
| Age | 52 |
| Address | Tavor Building, Yokne'am, Israel, 2069206 |
| Phone | 972 4 909 6313 |
| Web | https://www.inmodemd.com |
InMode Management Efficiency
The company has return on total asset (ROA) of 0.105 % which means that it generated a profit of $0.105 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2105 %, meaning that it created $0.2105 on every $100 dollars invested by stockholders. InMode's management efficiency ratios could be used to measure how well InMode manages its routine affairs as well as how well it operates its assets and liabilities. At present, InMode's Return On Equity is projected to increase slightly based on the last few years of reporting. At present, InMode's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 8.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 2.3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Georgia Melenikiotou | Inspire Medical Systems | 61 | |
| John Rondoni | Inspire Medical Systems | 44 | |
| Daveen Chopra | Edwards Lifesciences Corp | 45 | |
| Andrea Wainer | Abbott Laboratories | 55 | |
| Didier Deltort | Zimmer Biomet Holdings | 52 | |
| Vance Brown | Boston Scientific Corp | 54 | |
| Louis Morrone | Abbott Laboratories | 44 | |
| Michael Pederson | Abbott Laboratories | 59 | |
| Waleed MD | TransMedics Group | 56 | |
| Lisa Tatum | Stryker | 53 | |
| Janet Byk | Inari Medical | N/A | |
| Carrie Nichol | Zimmer Biomet Holdings | 40 | |
| Elaine Leavenworth | Abbott Laboratories | 65 | |
| Sean Lennon | Medtronic PLC | N/A | |
| Andrew Hykes | Inari Medical | 51 | |
| Todd Brinton | Edwards Lifesciences Corp | N/A | |
| Sean Christensen | DexCom Inc | N/A | |
| Ross Sylvia | Tandem Diabetes Care | N/A | |
| Paul Flynn | DexCom Inc | 55 | |
| Wilfred Zuilen | Zimmer Biomet Holdings | 54 | |
| John Carey | TransMedics Group | 59 | |
Management Performance
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.11 |
InMode Leadership Team
Elected by the shareholders, the InMode's board of directors comprises two types of representatives: InMode inside directors who are chosen from within the company, and outside directors, selected externally and held independent of InMode. The board's role is to monitor InMode's management team and ensure that shareholders' interests are well served. InMode's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, InMode's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Kreindel, CTO Director | ||
| Yair Malca, Chief Officer | ||
| Alon Yaari, Vice Operations | ||
| Spero MD, Chief Officer | ||
| Moshe Mizrahy, Chairman CEO | ||
| Shakil Lakhani, President America | ||
| Nava TalLauner, Chief Officer |
InMode Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is InMode a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.36 % | ||||
| Operating Margin | 0.37 % | ||||
| Current Valuation | 756.96 M | ||||
| Shares Outstanding | 76.25 M | ||||
| Shares Owned By Insiders | 10.75 % | ||||
| Shares Owned By Institutions | 64.20 % | ||||
| Number Of Shares Shorted | 6.44 M | ||||
| Price To Earning | 20.78 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether InMode is a strong investment it is important to analyze InMode's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact InMode's future performance. For an informed investment choice regarding InMode Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMode. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade InMode Stock refer to our How to Trade InMode Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMode. If investors know InMode will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMode listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.204 | Earnings Share 1.83 | Revenue Per Share 5.148 | Quarterly Revenue Growth 0.058 | Return On Assets 0.105 |
The market value of InMode is measured differently than its book value, which is the value of InMode that is recorded on the company's balance sheet. Investors also form their own opinion of InMode's value that differs from its market value or its book value, called intrinsic value, which is InMode's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMode's market value can be influenced by many factors that don't directly affect InMode's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMode's value and its price as these two are different measures arrived at by different means. Investors typically determine if InMode is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMode's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.